Quarterly Result13 Feb 2026, 01:32 pm
Blue Jet Healthcare Ltd Approves Unaudited Standalone Financial Results for Q3 and Nine Months of FY2025-26
AI Summary
Blue Jet Healthcare Ltd held a board meeting on February 13, 2026, and approved the unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The company, which is engaged in manufacturing Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products, reported revenues of INR 192,414 million and INR 689,540 million for the quarter and nine months ended December 31, 2025, respectively. The company does not have any subsidiaries, associates, or joint ventures as of December 31, 2025.
Key Highlights
- Blue Jet Healthcare Ltd approved the unaudited standalone financial results for Q3 and nine months of FY2025-26.
- The company reported revenues of INR 192,414 million for the quarter ended December 31, 2025.
- The company reported revenues of INR 689,540 million for the nine months ended December 31, 2025.
- The company is not required to prepare consolidated financial statements as it does not have any subsidiaries, associates, or joint ventures.
- The financial results have been reviewed by the Audit Committee, Board of Directors, and the Statutory Auditor of the Company.
Price Impact
More from BLUEJET